Maryam Emami, MD
Family Medicine · Prescott, AZNPI 1164876439
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 138 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations.
Across 138 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$408
- E.r. Squibb & Sons, L.L.C.$247
- GSK$164
- Amgen$163
- AstraZeneca$152
- Lilly USA, LLC$139
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,437100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 25 | $408 |
| E.r. Squibb & Sons, L.L.C. | 14 | $247 |
| GSK | 9 | $164 |
| Amgen | 11 | $163 |
| AstraZeneca | 10 | $152 |
| Lilly USA, LLC | 8 | $139 |
| Galderma Laboratories, L.p. | 4 | $71 |
| Bayer | 3 | $69 |
| Scilex Pharmaceuticals Inc. | 4 | $68 |
| Boehringer Ingelheim | 3 | $63 |
| Exact Sciences | 3 | $61 |
| Pfizer | 3 | $59 |
| Stryker | 1 | $59 |
| Radius Health, Inc. | 3 | $57 |
| Sanofi-aventis U.S. LLC | 4 | $57 |
| Kowa Pharmaceuticals America, Inc. | 4 | $53 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $51 |
| Novo Nordisk | 2 | $47 |
| Dexcom, Inc. | 2 | $46 |
| Astellas Pharma US Inc | 2 | $43 |
| Merz Pharmaceuticals, LLC | 1 | $43 |
| Paratek Pharmaceuticals, Inc. | 2 | $43 |
| Abbott | 2 | $32 |
| Phadia US Inc. | 2 | $31 |
| Amarin Pharma, Inc. | 2 | $28 |
| Currax Pharmaceuticals LLC | 2 | $28 |
| Nestle Healthcare Nutrition Inc. | 1 | $22 |
| Neurelis, Inc. | 1 | $22 |
| Bioventus LLC | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Merz North America, Inc. | 1 | $19 |
| Endo Pharmaceuticals Inc. | 1 | $17 |
| Biogen | 1 | $12 |
| Boston Scientific | 1 | $12 |
| Esperion Therapeutics, Inc. | 1 | $11 |
How this compares
$2,437 in reported general payments places this provider in the 85th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 30 | $49,049 |
| OzempicSemaglutide | 40 | $47,090 |
| JardianceEmpagliflozin | 26 | $33,203 |
| EliquisApixaban | 20 | $16,557 |
| FarxigaDapagliflozin Propanediol | 12 | $14,961 |
| Bydureon BciseExenatide Microspheres | 11 | $11,307 |
| Atorvastatin Calcium | 342 | $2,906 |
| Ipratropium Bromide | 120 | $2,591 |
| Levothyroxine Sodium | 279 | $2,353 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 89 | $2,074 |
| ProgesteroneProgesterone, Micronized | 28 | $2,048 |
| Estradiol | 27 | $2,041 |
| Losartan Potassium | 202 | $1,918 |
| Omeprazole | 127 | $1,667 |
| Rosuvastatin Calcium | 116 | $1,614 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $139 | $49,04930 claims |
| Novo NordiskOzempic | $47 | $47,09040 claims |
| Boehringer IngelheimJardiance | $63 | $33,20326 claims |
| PfizerEliquis | $59 | $16,55720 claims |
| AstraZenecaFarxiga | $152 | $14,96112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Prescott
- Edward KalpasPrescott$59K
- Douglas CunninghamPhoenix$1.8M
- Mitchell EdelsteinPhoenix$741K
- Lorena Jauregui-CovarrubiasYuma$491K
- Sam FereidouniScottsdale$486K
- Jessica BlancoChandler$447K
- Heather ElwoodPhoenix$236K
- Ryan CaseyYuma$231K
- Suzanne BentzMesa$174K
- Brent AllanParadise Valley$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.